iNtRON Biotechnology Inc Market Cap ($57.85 Million)
Market Cap & Net Worth: iNtRON Biotechnology Inc (048530)
iNtRON Biotechnology Inc market cap. iNtRON Biotechnology Inc (KQ:048530) has a market capitalization of $57.85 Million (₩85.36 Billion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #21126 globally and #1222 in its home market, demonstrating a -11.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying iNtRON Biotechnology Inc's stock price ₩2700.00 by its total outstanding shares 31613982 (31.61 Million). Also see iNtRON Biotechnology Inc (048530) cash conversion ratio for how efficiently the company converts equity into cash flow.
iNtRON Biotechnology Inc Market Cap History (2015–2026)
iNtRON Biotechnology Inc market cap history from 2015 to 2026. Data shows change from $581.67 Million to $57.85 Million (-16.89% CAGR). Check iNtRON Biotechnology Inc stock quote for real-time trading data and today's change.
Index Memberships
iNtRON Biotechnology Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$203.83 Billion | 0.03% | #551 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$203.83 Billion | 0.03% | #551 of 1384 |
Weight: iNtRON Biotechnology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
iNtRON Biotechnology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how iNtRON Biotechnology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of iNtRON Biotechnology Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.02x
iNtRON Biotechnology Inc's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $581.67 Million | $11.84 Billion | $1.56 Billion | 0.05x | 0.37x |
| 2016 | $327.79 Million | $10.22 Billion | -$610.38 Million | 0.03x | N/A |
| 2017 | $478.83 Million | $10.96 Billion | -$8.73 Billion | 0.04x | N/A |
| 2018 | $461.69 Million | $20.58 Billion | $8.71 Billion | 0.02x | 0.05x |
| 2019 | $332.08 Million | $8.35 Billion | -$3.19 Billion | 0.04x | N/A |
| 2020 | $596.67 Million | $45.43 Billion | $14.95 Billion | 0.01x | 0.04x |
| 2021 | $450.98 Million | $29.31 Billion | $9.73 Billion | 0.02x | 0.05x |
| 2022 | $174.18 Million | $14.01 Billion | $5.71 Billion | 0.01x | 0.03x |
| 2023 | $188.11 Million | $9.59 Billion | -$9.70 Billion | 0.02x | N/A |
| 2024 | $120.19 Million | $6.42 Billion | -$2.59 Billion | 0.02x | N/A |
Competitor Companies of 048530 by Market Capitalization
Companies near iNtRON Biotechnology Inc in the global market cap rankings as of November 4, 2026. Also see iNtRON Biotechnology Inc assets under control for a full breakdown of the balance sheet.
Key companies related to iNtRON Biotechnology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of iNtRON Biotechnology Inc (2015–2026)
Market capitalization of iNtRON Biotechnology Inc from 2015 to today. Between 2015 and today, iNtRON Biotechnology Inc's market cap moved from $581.67 Million to $ 57.85 Million, with a yearly change of -16.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩57.85 Million | -16.92% |
| 2025 | ₩69.63 Million | -42.07% |
| 2024 | ₩120.19 Million | -36.10% |
| 2023 | ₩188.11 Million | +8.00% |
| 2022 | ₩174.18 Million | -61.38% |
| 2021 | ₩450.98 Million | -24.42% |
| 2020 | ₩596.67 Million | +79.68% |
| 2019 | ₩332.08 Million | -28.07% |
| 2018 | ₩461.69 Million | -3.58% |
| 2017 | ₩478.83 Million | +46.08% |
| 2016 | ₩327.79 Million | -43.65% |
| 2015 | ₩581.67 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of iNtRON Biotechnology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $57.85 Million USD |
| MoneyControl | $57.85 Million USD |
| MarketWatch | $57.85 Million USD |
| marketcap.company | $57.85 Million USD |
| Reuters | $57.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About iNtRON Biotechnology Inc
iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.